- Home
- NMFC vs AQST Comparison
NMFC vs AQST Comparison
Compare NMFC & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMFC | AQST |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.4M | 521.0M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | NMFC | AQST |
|---|---|---|
| Price | $7.87 | $4.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $8.63 | ★ $9.00 |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | ★ 16.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $14.23 |
| Revenue Next Year | N/A | $58.36 |
| P/E Ratio | $12.51 | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $7.52 | $2.20 |
| 52 Week High | $11.20 | $7.55 |
Technical Indicators
Market Signals| Indicator | NMFC | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 38.26 | 51.51 |
| Support Level | $7.52 | $3.69 |
| Resistance Level | $8.28 | $4.46 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 41.69 | 47.66 |
Price Performance
Historical ComparisonAbout NMFC New Mountain Finance Corporation
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.